GMAB

Genmab A/S

About GMAB

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Buy US stocks in Australia starting with GMAB. Open an account and start investing today!

Market Capitalisation

$23.65B

Price-earnings ratio

Dividend yield

0.00%

Volume

393.04K

High today

$36.19

Low today

$35.80

Open price

$36.06

52-week high

$47.50

52-week low

$26.19

GMAB FAQs

How much is one share of Genmab A/S?

One share of Genmab A/S is valued at $35.96.

What is the ticker symbol for Genmab A/S?

The ticker symbol for Genmab A/S is GMAB.

How do I buy GMAB shares in Australia?

To buy GMAB stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:

Sign up in minutes, all you need is some I.D.
Choose Stake Wall St
Deposit directly into your Stake wallet and you're ready to invest in GMAB

What is the 52-week high for Genmab A/S stock?

The Genmab A/S 52-week high stock price is $47.50.

What is the 52-week low for Genmab A/S stock?

The Genmab A/S 52-week low stock price is $26.19.

What is the market capitalisation of Genmab A/S GMAB?

As of 21/03/2023 Genmab A/S has a market cap of $24B.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.